The global oral microbiome products market size was valued at USD 1.35 billion in 2025 and is expected to reach USD 3.61 billion by 2033, expanding at a CAGR of 13.1% from 2026 to 2033. The market is growing steadily as awareness of the strong connection between oral health and overall systemic health increases.
Consumers and healthcare professionals are recognizing that an imbalance in oral bacteria is linked to dental issues such as cavities, gum disease, and bad breath, as well as broader health conditions, including diabetes, cardiovascular diseases, and respiratory infections. For instance, according to the International Diabetes Federation Diabetes Atlas (2025), 11.1% of adults (1 in 9) are living with diabetes, with 46% unaware of their condition. By 2050, cases are projected to reach 853 million (1 in 8 adults), marking a 46% increase and highlighting a significant global health challenge. This growing disease burden is reinforcing the importance of preventive oral care solutions, thereby accelerating demand for microbiome-based products that support both oral and overall health.
In addition, market growth is driven by the increasing global prevalence of oral diseases and the rising burden of non-communicable diseases. Oral conditions such as dental caries, gingivitis, and periodontal disease are among the most common health issues worldwide, affecting a large proportion of both adults and children. For instance, in March 2025, according to the WHO, oral diseases, although largely preventable, represent a significant global health burden affecting people across all age groups throughout their lifetime. These conditions often lead to pain, discomfort, disfigurement, and in severe cases, even death, significantly reducing quality of life. Prevention and treatment of oral health problems are often costly and are not commonly included in national universal health coverage (UHC) benefit packages, limiting access to care. As a result, most low- and middle-income countries face inadequate availability of essential preventive and treatment services. Oral diseases are strongly linked to modifiable risk factors such as high sugar intake, tobacco use, alcohol consumption, and poor oral hygiene, which are also associated with other non-communicable diseases, along with broader social and commercial determinants of health.
The development of microbiome-based products requires strong scientific expertise in microbiology, dentistry, biotechnology, and clinical research. As a result, companies are forming partnerships with academic institutions, research organizations, and biotechnology firms to better understand the complex ecosystem of the oral microbiome and identify effective probiotic strains. These collaborations are also helping in the development of clinically validated products. Since regulatory approval and dentist acceptance depend heavily on scientific evidence, joint research initiatives and clinical trials play a crucial role in building product credibility.
In April 2026, Dr. Colleen Cutcliffe, Co-founder and CEO of Pendulum Therapeutics, stated that the collaboration demonstrates a shared commitment to advancing robust microbiome research.
"Our collaboration represents an important milestone in the continued advancement of microbiome science," said Cutcliffe. "Together, we are committed to conducting rigorous clinical research that deepens our understanding of how the gut microbiome influences systemic health - from metabolic function to skin health and women's health."
Strategic collaborations between large consumer health companies and innovative startups are accelerating product innovation and market expansion. Established companies bring strong distribution networks, brand recognition, and manufacturing capabilities, while startups contribute advanced scientific research and novel microbial technologies. In April 2026, Pendulum Therapeutics expanded its clinical research collaboration with Mayo Clinic to advance microbiome-based research. The collaboration will focus on exploring new applications of microbiome interventions in women’s health and dermatology. This initiative aims to strengthen clinical understanding of microbiome science for broader therapeutic use. Such collaborations are expected to accelerate commercialization, enhance product credibility, and drive the adoption of microbiome-based solutions across new health and wellness segments.
This product will be delivered within 1-3 business days.
Consumers and healthcare professionals are recognizing that an imbalance in oral bacteria is linked to dental issues such as cavities, gum disease, and bad breath, as well as broader health conditions, including diabetes, cardiovascular diseases, and respiratory infections. For instance, according to the International Diabetes Federation Diabetes Atlas (2025), 11.1% of adults (1 in 9) are living with diabetes, with 46% unaware of their condition. By 2050, cases are projected to reach 853 million (1 in 8 adults), marking a 46% increase and highlighting a significant global health challenge. This growing disease burden is reinforcing the importance of preventive oral care solutions, thereby accelerating demand for microbiome-based products that support both oral and overall health.
In addition, market growth is driven by the increasing global prevalence of oral diseases and the rising burden of non-communicable diseases. Oral conditions such as dental caries, gingivitis, and periodontal disease are among the most common health issues worldwide, affecting a large proportion of both adults and children. For instance, in March 2025, according to the WHO, oral diseases, although largely preventable, represent a significant global health burden affecting people across all age groups throughout their lifetime. These conditions often lead to pain, discomfort, disfigurement, and in severe cases, even death, significantly reducing quality of life. Prevention and treatment of oral health problems are often costly and are not commonly included in national universal health coverage (UHC) benefit packages, limiting access to care. As a result, most low- and middle-income countries face inadequate availability of essential preventive and treatment services. Oral diseases are strongly linked to modifiable risk factors such as high sugar intake, tobacco use, alcohol consumption, and poor oral hygiene, which are also associated with other non-communicable diseases, along with broader social and commercial determinants of health.
The development of microbiome-based products requires strong scientific expertise in microbiology, dentistry, biotechnology, and clinical research. As a result, companies are forming partnerships with academic institutions, research organizations, and biotechnology firms to better understand the complex ecosystem of the oral microbiome and identify effective probiotic strains. These collaborations are also helping in the development of clinically validated products. Since regulatory approval and dentist acceptance depend heavily on scientific evidence, joint research initiatives and clinical trials play a crucial role in building product credibility.
In April 2026, Dr. Colleen Cutcliffe, Co-founder and CEO of Pendulum Therapeutics, stated that the collaboration demonstrates a shared commitment to advancing robust microbiome research.
"Our collaboration represents an important milestone in the continued advancement of microbiome science," said Cutcliffe. "Together, we are committed to conducting rigorous clinical research that deepens our understanding of how the gut microbiome influences systemic health - from metabolic function to skin health and women's health."
Strategic collaborations between large consumer health companies and innovative startups are accelerating product innovation and market expansion. Established companies bring strong distribution networks, brand recognition, and manufacturing capabilities, while startups contribute advanced scientific research and novel microbial technologies. In April 2026, Pendulum Therapeutics expanded its clinical research collaboration with Mayo Clinic to advance microbiome-based research. The collaboration will focus on exploring new applications of microbiome interventions in women’s health and dermatology. This initiative aims to strengthen clinical understanding of microbiome science for broader therapeutic use. Such collaborations are expected to accelerate commercialization, enhance product credibility, and drive the adoption of microbiome-based solutions across new health and wellness segments.
Global Oral Microbiome Products Market Report Segmentation
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global oral microbiome products market report based on formulation type, application, end-user, and region:Formulation Type Outlook (Revenue, USD Million, 2021-2033)
- Probiotics
- Postbiotics
- Prebiotics
- Synbiotics
- Non-Biotic Bioactives
Application Outlook (Revenue, USD Million, 2021-2033)
- Caries Management
- Periodontal & Gum Health
- Halitosis
- Preventive/General Wellness
- Xerostomia
End-user Outlook (Revenue, USD Million, 2021-2033)
- Adult
- Pediatric
- Geriatric
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Thailand
- Australia
- South Korea
- Latin America
- Brazil
- Argentina
- Columbia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Oral Microbiome Products Market Variables, Trends, & Scope
Chapter 4. Oral Microbiome Products Market: Formulation Type Estimates & Trend Analysis
Chapter 5. Oral Microbiome Products Market: Application Estimates & Trend Analysis
Chapter 6. Oral Microbiome Products Market: End User Estimates & Trend Analysis
Chapter 7. Oral Microbiome Products Market: Regional Estimates & Trend Analysis by Formulation Type, Application, and End User
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Unilever
- Colgate-Palmolive Company
- Procter & Gamble
- BLIS Technologies
- BioGaia
- Oragenics, Inc
- ProBiora Health
- Lallemand Inc.
- Sunstar Suisse S.A.
- Ostia Sciences Inc
- Revitin
- NatureWise
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | April 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 1.35 Billion |
| Forecasted Market Value ( USD | $ 3.61 Billion |
| Compound Annual Growth Rate | 13.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
